MindMed
Created in 2019
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
395 34,191Activities
Technologies
Entity types
Location
One World Trade Center, 285 Fulton St, New York, NY 10006, USA
New York
United States of America
Employees
Scale: 51-200
Estimated: 102
Engaged corporates
4
0 3Added in Motherbase
1 year, 7 months ago
deeptech Value proposition
MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders
MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
Rethinking Brain Health | MindMed
MindMed works to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain and neurology.
https://mindmed.co/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Biotechnology Innovation Organization | Other 10 Jun 2024 | | |
 MSD Pharmaceutical, Pharmaceutical Manufacturing | MSD Pharmaceutical, Pharmaceutical Manufacturing | Other 4 Nov 2019 | | |
 Bayer Pharmaceutical, Chemistry, Chemical Manufacturing | Bayer Pharmaceutical, Chemistry, Chemical Manufacturing | Other 12 Sep 2019 | | |
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 26 Nov 2023 | | |